Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6452478 | 0.89 | KCNA3 (0.34) | BRD4KCNA3ALDH1A1KDM4EMEN1 | |
| SCHEMBL6449195 | 0.84 | PTPN11 (0.47) | MEN1POLBKMT2A | |
| SCHEMBL6449197 | 0.84 | PTPN11 (0.47) | MEN1POLBKMT2A | |
| SCHEMBL6452220 | 0.82 | BRD4 (0.36) | BRD4KCNA3ALDH1A1HTTKDM4E | |
| SCHEMBL6459639 | 0.82 | NAT1 (0.46) | MEN1NPC1KMT2A | |
| SCHEMBL6459642 | 0.82 | NAT1 (0.46) | MEN1NPC1KMT2A | |
| SCHEMBL6448172 | 0.77 | PTPN11 (0.49) | HTTNPC1 | |
| SCHEMBL6448177 | 0.77 | PTPN11 (0.49) | HTTNPC1 | |
| SCHEMBL6448239 | 0.74 | RARB (0.39) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6447869 | 0.74 | NAT1 (0.43) | MEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | INCYTE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004066952-A2 | BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES | INCYTE CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | AR, CCNT1, BRD1 | BRD4 72/4885KCNA3 1674/4885ALDH1A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.